Clinical Trial Update: Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 dose-escalation and expansion trial of NC-6300 in advanced solid tumors and soft tissue sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma
• Soft Tissue Sarcoma
• Solid Tumor

Drugs mentioned

• NC-6300

Snippet

Sponsor: NanoCarrier Co., Ltd. | Conditions: Solid Tumor, Soft Tissue Sarcoma | Phase 1, Phase 2 | Status: UNKNOWN